EGFR and neoplasm: Given that tumors are heterogenous, particularly when metastasized and subjected to several lines of drug pressure, tumor cells harboring specific oncogenic mutations (i.e. KRAS) may confer EGFR-targeted mAb resistance to otherwise treatment-sensitive WT cells via paracrine signaling [82,84].